Page last updated: 2024-11-04

amobarbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2164
CHEMBL ID267894
CHEBI ID2673
SCHEMBL ID43780
SCHEMBL ID15364946
MeSH IDM0001000

Synonyms (125)

Synonym
BIDD:PXR0091
nsc 10815
amal
robarb
2,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-
barbituric acid, 5-ethyl-5-isopentyl-
barbamil
talamo
5-ethyl-5-isopentylbarbituric acid
sednotic
amobarbitone
dorlotyn
component of 15-90
nsc-120800
barbamyl acid
somnal
wln: t6vmvmv fhj f2 f2y1&1
5-isoamyl-5-ethylbarbituric acid
pentymalum
eunoctal
amospan
nsc120800
sumital
component of amo-dextrosule
5-ethyl-5-(3-methylbutyl)-2,6(1h,3h,5h)-pyrimidinetrione
amylbarbitone
5-ethyl-5-isoamylbarbituric acid
amasust
amylobarbital
ethylisopentylbarbituric acid
component of dexamyl
5-ethyl-5-isoamylmalonyl urea
mylodorm
pentymal
5-ethyl-5-(3-methylbutyl)barbituric acid
stadadorm
schiwanox
isomytal
component of q-caps
amybal
dormytal
amytal
amylobarbitone
amital
binoctal
barbamyl
isoamylethylbarbituric acid
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-
nsc32406
nsc-32406
DIVK1C_000994
KBIO1_000994
CHEBI:2673 ,
5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1h,3h,5h)-trione
5-ethyl-5-(3-methylbutyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
ccris 5454
5-ethyl-5-isopentylbarbitursaeure
amobarbitalum [inn-latin]
einecs 200-330-7
amobarbitale [dcit]
hsdb 3286
isomyl
nsc10815
nsc-10815
CBDIVE_006514
OPREA1_587446
IDI1_000994
C07536
amobarbital
57-43-2
DB01351
amobarbital (jp17/inn)
isomytal (tn)
D00555
NINDS_000994
virovyvqcglcii-uhfffaoysa-
inchi=1/c11h18n2o3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7h,4-6h2,1-3h3,(h2,12,13,14,15,16)
amobarbital cii
CHEMBL267894
5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
NCGC00247711-01
tox21_112866
cas-57-43-2
dtxcid0081
dtxsid9020081 ,
gwh6ij239e ,
amobarbital [usp:inn:ban:jan]
amobarbitalum
amobarbitale
unii-gwh6ij239e
amobarbital [hsdb]
amobarbital cii [usp-rs]
amobarbital [ep impurity]
amobarbital [mart.]
amobarbital [mi]
amobarbital [jan]
amobarbital [inn]
amobarbital [who-dd]
amobarbital [vandf]
SCHEMBL43780
component of dexamyl (salt/mix)
component of q-caps (salt/mix)
component of 15-90 (salt/mix)
VIROVYVQCGLCII-UHFFFAOYSA-N
5-ethyl-5-isopentyl-2,4,6(1h,3h,5h)-pyrimidinetrione #
barbituric acid, 5-ethyl-5-isoamyl-
component of amo-dextrosule (salt/mix)
dexamyl (salt/mix)
SCHEMBL15364946
isopentobarbital
amobarbital 0.1 mg/ml in methanol
amobarbital 1.0 mg/ml in methanol
Q415850
barbituric acid, 5-ethyl-5-isopentyl
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-,
amobarbital (mart.)
euroctal
statadorm
amobarbital cii (usp-rs)
amobarbital (ep impurity)
amobarbitalum (inn-latin)
isoamyethylbarbituric acid
n05ca02
5-ethyl-5-(3-methylbutyl)-2,4,6-(1h,3h,5h)-pyrimidinetrione
amobarbital (usp:inn:ban:jan)

Research Excerpts

Overview

Amobarbital interview is a safe and simple technique to discriminate functional from organic illness. It avoids unnecessary medical and surgical treatment, neglected illness, and inappropriate disposition.

ExcerptReferenceRelevance
"Amobarbital is a reversible inhibitor at the rotenone site of complex I."( Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria.
Chen, Q; Hoppel, CL; Lesnefsky, EJ, 2006
)
1.28
"The amobarbital interview is a safe and simple technique to discriminate functional from organic illness, thus avoiding unnecessary medical and surgical treatment, neglected illness, and inappropriate disposition."( The amobarbital interview.
Fauman, BJ; Wettstein, RM, 1979
)
1.3

Effects

Amobarbital has been found to coelute with 25-hydroxycholecalciferol (25OHD3) on a normal phase high performance liquid chromatographic system and cause subsequent interference in the UV detection and plasma transport competitive protein binding assay for this vitamin D metabolite.

ExcerptReferenceRelevance
"The amobarbital interview has been a diagnostic and therapeutic tool for almost 70 years. "( The amobarbital interview revisited: a review of the literature since 1966.
Kavirajan, H,
)
1.25
"The amobarbital interview has been in use for over 50 years. "( The amobarbital interview in a general hospital setting, friend or foe: a case report.
Baron, DA; Nagy, R, 1988
)
1.39
"Amobarbital has been found to coelute with 25-hydroxycholecalciferol (25OHD3) on a normal phase high performance liquid chromatographic system and cause subsequent interference in the UV detection and plasma transport competitive protein binding assay for this vitamin D metabolite. "( Amobarbital interactions with 25-hydroxycholecalciferol: effects on the extraction, quantification, and competitive protein binding in vitro.
Beecher, GR; Howe, JC; Majors, SH, 1985
)
3.15

Treatment

Amobarbital was used to test the hypothesis that damage to mitochondrial respiration occurs mainly during ischemia. The treatment decreased cardiac injury and protected respiration.

ExcerptReferenceRelevance
"Amobarbital treatment decreased cardiac injury and protected respiration."( Intermediary metabolism and fatty acid oxidation: novel targets of electron transport chain-driven injury during ischemia and reperfusion.
Chen, Q; Hollander, JM; Hu, Y; Lesnefsky, EJ; Thompson, J; Younus, M, 2018
)
1.2
"Amobarbital-treated hearts received drug for 1 min before ischemia."( Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria.
Chen, Q; Hoppel, CL; Lesnefsky, EJ, 2006
)
1.28
"Amobarbital treatment immediately before ischemia was used to test the hypothesis that damage to mitochondrial respiration occurs mainly during ischemia and that protection of mitochondria during ischemia leads to decreased cardiac injury with reperfusion."( Reversible blockade of electron transport during ischemia protects mitochondria and decreases myocardial injury following reperfusion.
Chen, Q; Hoppel, CL; Lesnefsky, EJ; Moghaddas, S, 2006
)
1.06

Toxicity

Etomidate is a safe alternative to sodium amobarbital for the Wada test for determining the hemispheric dominance for speech and in predicting the memory outcome. Propofol can continue to be used in Wada procedures with confidence.

ExcerptReferenceRelevance
" It is concluded that the toxic effects of barbiturates are partially due to the inhibition of mitochondrial respiration at the level of NADH-dehydrogenase."( [Possible biochemical mechanism of the toxic effects of barbiturates].
Cheistiakov, VV; Ratnikova, LA, 1978
)
0.26
" DSA performed by experienced angiographers is a safe procedure that can provide critical diagnostic information."( Safety of cerebral digital subtraction angiography in children: complication rate analysis in 241 consecutive diagnostic angiograms.
Burger, IM; Gailloud, P; Jordan, LC; Murphy, KJ; Tamargo, RJ, 2006
)
0.33
" This included the electroencephalographic and motor effects of etomidate injection and their time course (onset and recovery), Wada test results (language laterality and memory performance), and all adverse events during the procedure."( Intracarotid etomidate is a safe alternative to sodium amobarbital for the Wada test.
Cohn, M; Manninen, P; Mariappan, R; McAndrews, MP; Tai, P; Valiante, T; Venkatraghavan, L, 2013
)
0.64
"From our experience, etomidate is a safe alternative to sodium amobarbital for the Wada test for determining the hemispheric dominance for speech and in predicting the memory outcome."( Intracarotid etomidate is a safe alternative to sodium amobarbital for the Wada test.
Cohn, M; Manninen, P; Mariappan, R; McAndrews, MP; Tai, P; Valiante, T; Venkatraghavan, L, 2013
)
0.88
" With regard to safety, there were no differences found in average rate or severity of adverse effects."( The safety and efficacy of propofol as a replacement for amobarbital in intracarotid Wada testing of presurgical patients with epilepsy.
Barrash, J; Granner, M; Greider, A; Jones, R; Manzel, K; McCleary, K, 2018
)
0.73
"These findings support previous studies indicating that propofol is as safe and efficacious as amobarbital, and can continue to be used in Wada procedures with confidence."( The safety and efficacy of propofol as a replacement for amobarbital in intracarotid Wada testing of presurgical patients with epilepsy.
Barrash, J; Granner, M; Greider, A; Jones, R; Manzel, K; McCleary, K, 2018
)
0.94
"The EST was found to be successful and safe in lateralizing language in most of our drug refractory pediatric epilepsy cohort."( Reliability and safety of Etomidate speech test in children with drug resistant focal epilepsy.
Carter Snead, O; Go, C; Gulati, P; Jain, P; Kerr, E; Lou Smith, M; Muthusami, P; Shroff, M; Whitney, R, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
"Many pharmacodynamic (PD) models may be generalized in the form E(t) = N(L[c(t)]), where E(t) is a recorded effect response, c(t) is a sampled drug level, N is a nonlinear autonomic function, and L is a linear operator that commonly is a convolution operation."( A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling.
Danhof, M; Mandema, JW; Veng-Pedersen, P, 1991
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate clinical therapeutic effect of post-stroke shoulder pain treated by acupuncture combined with Tuina."( [Double-center randomized controlled trial on post-stroke shoulder pain treated by electroacupuncture combined with Tuina].
Huang, L; Li, N; Qiao, XL; Tian, FW; Wang, CW; Wen, Q; Yu, PM; Zhou, X, 2012
)
0.38
", combined with traditional Tuina manipulations; in rehabilitation group, the rehabilitation methods such as the electrostimulation through nervus cutaneus and the squeezing and stabilizing manipulations of Proprioceptive Neuromuscular Facilitation (PNF), etc."( [Double-center randomized controlled trial on post-stroke shoulder pain treated by electroacupuncture combined with Tuina].
Huang, L; Li, N; Qiao, XL; Tian, FW; Wang, CW; Wen, Q; Yu, PM; Zhou, X, 2012
)
0.38
" The comprehensive treatment of fire needles at bones combined with cupping and Tuina on local area of affected knee was applied in the comprehensive group."( [Clinical observation on fire needles at bones combined with cupping and Tuina for knee osteoarthritistis].
Gao, YL; Guo, JX; Yao, JH, 2013
)
0.39
"The comprehensive treatment of fire needles at bones combined with cupping and Tuina, considered as a better therapy for knee osteoarthritis, could improve joint pain, swelling and action function, which is superior to the conventional acupuncture."( [Clinical observation on fire needles at bones combined with cupping and Tuina for knee osteoarthritistis].
Gao, YL; Guo, JX; Yao, JH, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Intracarotid injection of a low dosage of amobarbital (75 mg, 5% solution) was studied in 30 temporal lobectomy candidates while naming achromatic, incongruously, and congruously colored pictorial objects and reading real, nonsense, and embedded words. With extra pre-test teaching and emotional preparation, adjusted amobarBital dosage for younger patients, and simplified test items tailored to the child's abilities, language and memory testing were accomplished after at least one injection for 19 of patients.

ExcerptRelevanceReference
"A double-blind crossover trial comparing lorazepam at two dosage levels with amylobarbitone supported previous reports of the effective anxiolytic action of the drug."( A comparison of high- and low-dose lorazepam with amylobarbitone in patients with anxiety states.
McClelland, HA; Newell, DJ; Schapira, K, 1977
)
0.26
" Twenty anxious patients were treated with medazepam, diazepam, chlordiazepoxide, amylobarbitone and placebo, each given in flexible dosage for 2-4 weeks."( Plasma concentrations of benzodiazepines.
Bond, AJ; Hailey, DM; Lader, MH, 1977
)
0.26
"Twenty-four anxious inpatients were treated with diazepam, amylobarbitone and placebo, each given in flexible dosage for one week, according to a fully-balanced design."( Plasma concentrations of diazepam, noradiazepam and amylobarbitone after short-term treatment of anxious patients.
Ferrario, L; Lader, M; Preziati, L; Tansella, M; Tognoni, G; Zimmermann Tansella, C, 1978
)
0.26
" Twenty-four anxious inpatients were treated with diazepam, amylobarbitone sodium and placebo in flexible dosage for 1 week."( A comparison of the clinical and psychological effects of diazepam and amylobarbitone in anxious patients.
Lader, M; Tansella, CZ; Tansella, M, 1979
)
0.26
" After each week of a flexible dosage treatment with either diazepam, amylobarbitone or placebo anxious patients were assessed by a comprehensive battery of psychiatrist's ratings, subjective tests and psychological performance tasks to detect the clinical and psychological effects of the drugs."( Psychological performance in anxious patients treated with diazepam.
Lader, M; Tansella, M; Zimmermann-Tansella, C, 1979
)
0.26
"The presence and mechanism of synergism of action between ethanol and amylobarbitone, phenobarbitone or methaqualone was determined by application of simple pharmacokinetic models to log dose-response curves and plasma concentration-time curves for the hypnotics alone or when ethanol was given concurrently."( Interaction of ethanol with amylobarbitone, phenobarbitone and methaqualone.
Reavey, PC; Tilstone, WJ, 1978
)
0.26
"For various reasons the dosage of drugs in early life is difficult and complicated."( [Drug metabolism in early life].
Netter, KJ, 1975
)
0.25
"Using isolated rat aortic strips (AS) and portal veins (PV), it was found that all of the barbiturates studied (thiopental, secobarbital, pentobarbital, amobarbital, phenobarbital, and barbital): a) inhibit development of spontaneous mechanical activity (vasomotion) in AS and PV in concentrations used to induce surgical anesthesia or concentrations used for anticonvulsive therapy; b) dose-dependent attenuate contractions induced by epinephrine and potassium (K+); c) cause non-competitive displacement of the dose-response curves of these vasoactive compounds; d) attenuate calcium (Ca++)-induced contractions of K+-depolarized AS and PV; e) rapidly relax drug-induced, as well as Ca++-induced, contractions of AS and PV."( Barbiturates and aortic and venous smooth-muscle function.
Altura, BM; Altura, BT, 1975
)
0.45
" The effect of administering activated charcoal at varying intervals after dosing on the blood drug-level profiles of paracetamol and amylobarbitone was assessed by comparison with the profiles obtained when charcoal therapy was withheld."( Studies with activated charcoal in the treatment of drug overdosage using the pig as an animal model.
Lipscomb, DJ; Widdop, B, 1975
)
0.25
" In cases with poor memory results high inattention scores may speak in favour of preoperative hemisphere memory testing or a repeat injection with reduced Amytal dosage before deciding upon the extent of a planned resection."( A compound score for estimating the influence of inattention and somnolence during the intracarotid amobarbital test.
Bilting, M; Hagberg, I; Hedström, A; Malmgren, K; Silfvenius, H; Starmark, JE, 1992
)
0.5
"Eighty-six patients with acute psychotic exacerbations were treated with fixed dosage regimens of oral fluphenazine up to 10-30 mg/day in randomized, double-blind studies."( Acute dystonia during fixed-dose neuroleptic treatment.
Friedman, E; Levinson, DF; Lo, ES; Simpson, GM; Singh, H, 1990
)
0.28
" No effect of seizure focus, sex, order of injection, or dosage was present."( Right cerebral specialization for tactile attention as evidenced by intracarotid sodium amytal.
Brooks, BS; Heilman, KM; Lee, GP; Loring, DW; Meador, KJ; Thompson, EE; Thompson, WO, 1988
)
0.27
" This has been applied to the analysis of some of these drugs in plasma taken from patients after therapeutic dosage and over-dosage."( A rapid micro-method for the screening and measurement of barbiturates and related compounds in plasma by gas-liquid chromatography.
Flanagan, RJ; Withers, G, 1972
)
0.25
" fast activity was more plentiful after drugs in either dosage than with placebo."( Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium.
Boyce, CR; Malpas, A; Rowan, AJ; Scott, DF, 1970
)
0.25
"A controlled double-blind trial of amitriptyline at two dosage levels (75 and 150 mg/day), amylobarbitone (150 mg/day), and an inert substance for a period of four weeks was conducted on four matched groups of women attending their general practitioners and suffering from a depressive illness."( Controlled trial of amitriptyline in general practice.
Blashki, TG; Davies, B; Mowbray, R, 1971
)
0.25
" Improvement occurred after a single dose of the anxiolytic drugs but did not occur until 10-18 days after daily dosing with standard tricylic antidepressants and the MAO inhibitor isocarboxazid."( Effects of selected drugs on spontaneously occurring abnormal behavior in beagles.
Barnett, A; Brody, PE; Eisenstein, N; Iorio, LC, 1983
)
0.27
" With extra pre-test teaching and emotional preparation, adjusted amobarbital dosage for younger patients, and simplified test items tailored to the child's abilities, language and memory testing were accomplished after at least one injection for 19 (86%) of patients."( Intracarotid amobarbital testing for language and memory dominance in children.
Szabó, CA; Wyllie, E, 1993
)
0.89
"Intracarotid injection of a low dosage of amobarbital (75 mg, 5% solution) was studied in 30 temporal lobectomy candidates while naming achromatic, incongruously, and congruously colored pictorial objects and reading real, nonsense, and embedded words."( Semantic, phonological, and perceptual changes following left and right intracarotid injection (Wada) with a low amytal dosage.
August, A; Fedio, P; Kufta, C; Patronas, N; Sato, S, 1997
)
0.56
" A condition for antidote effect of the Krebs intermediate was sufficiently high dosage (5 mmol/kg), further dose increase made no odds."( Intermediates of Krebs cycle correct the depression of the whole body oxygen consumption and lethal cooling in barbiturate poisoning in rat.
Ivnitsky, JJ; Malakhovsky, VN; Rejniuk, VL; Schäfer, TV, 2004
)
0.32
" Because of the differences among inter-individuals in the metabolic clearance of these drugs and their toxicity at certain levels of concentration in serum, the dosage should be regulated to maintain a therapeutic blood drugs level."( [Simultaneous analysis of theophylline, phenobarbital, amobarbital and carbamazepine in serum by high performance liquid chromatography].
Duan, S; Fu, S; Ren, Q, 1997
)
0.54
"The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use."( The Optimal Dose of Amobarbital in the Wada Test for the Presurgical Evaluation of Patients With Temporal Lobe Epilepsy.
Al Said, Y; Alqadi, K; Babtain, F; Baeesa, S; Bajammal, S; Kurdi, K; Madani, N,
)
0.84
" There was no statistical difference between the dosing given to patients who passed or failed the memory testing (101."( The Optimal Dose of Amobarbital in the Wada Test for the Presurgical Evaluation of Patients With Temporal Lobe Epilepsy.
Al Said, Y; Alqadi, K; Babtain, F; Baeesa, S; Bajammal, S; Kurdi, K; Madani, N,
)
0.45
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency33.67830.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency48.05700.000221.22318,912.5098AID743036
farnesoid X nuclear receptorHomo sapiens (human)Potency67.29690.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.81730.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID1130943Octanol-water partition coefficient, log P of nonionized form of compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID11918Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID38914Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1130945Inhibition of Arbacia egg cell division1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1145372Induction of hypnotic activity in rabbit1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID1130940Retention index of the compound by HPLC method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID169097Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1145374Induction of hypnotic activity in rat1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29351pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1130944Hypnotic activity in rabbit1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,357)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901764 (74.84)18.7374
1990's256 (10.86)18.2507
2000's237 (10.06)29.6817
2010's74 (3.14)24.3611
2020's26 (1.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.22 (24.57)
Research Supply Index7.92 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index99.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials151 (5.81%)5.53%
Reviews82 (3.16%)6.00%
Case Studies167 (6.43%)4.05%
Observational1 (0.04%)0.25%
Other2,196 (84.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA [NCT04589611]Phase 1/Phase 266 participants (Anticipated)Interventional2022-07-20Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]